France's Poxel Q3 revenue rises on higher TWYMEEG royalties

Poxel SA

Mon 06:56

Overview
France biopharma reported Q3 2026 revenue up 51% yr/yr, driven by TWYMEEG royalties
TWYMEEG net sales in Japan rose 29% yr/yr, triggering higher royalty rate for Poxel
Company generated positive net royalties for the first time as royalty rate increased to 10%

Outlook
Sumitomo Pharma expects TWYMEEG net sales to exceed JPY 10 bln in FY 2026
Upon JPY 10 bln sales milestone, Poxel to receive JPY 1 bln payment from Sumitomo Pharma

Result Drivers
TWYMEEG SALES GROWTH - Co said 29% yr/yr increase in TWYMEEG net sales in Japan drove higher royalties
ROYALTY RATE INCREASE - Royalty rate on TWYMEEG sales rose from 8% to 10% after sales exceeded JPY 5 bln threshold
RETROACTIVE ROYALTY ADJUSTMENT - Q3 revenue included retroactive adjustment to royalties for prior quarter

Company press release: ID:nBw2KCsF9a

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
 
EUR 1.95 mln
 

Reuters Recommended Reads
Oct 16 - Diagnostics firm Biomerica's Q1 revenue drops on lower clinical lab orders

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)